Cytosorbents Crp (CTSO) - Net Assets
Based on the latest financial reports, Cytosorbents Crp (CTSO) has net assets worth $2.19 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($40.56 Million) and total liabilities ($38.37 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore CTSO current and non-current assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.19 Million |
| % of Total Assets | 5.41% |
| Annual Growth Rate | N/A |
| 5-Year Change | -90.57% |
| 10-Year Change | N/A |
| Growth Volatility | 1157.95 |
Cytosorbents Crp - Net Assets Trend (2004–2025)
This chart illustrates how Cytosorbents Crp's net assets have evolved over time, based on quarterly financial data. Check Cytosorbents Crp tangible equity quality to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Cytosorbents Crp (2004–2025)
The table below shows the annual net assets of Cytosorbents Crp from 2004 to 2025. For live valuation and market cap data, see Cytosorbents Crp (CTSO) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $5.90 Million | -46.85% |
| 2024-12-31 | $11.11 Million | -52.28% |
| 2023-12-31 | $23.28 Million | -34.20% |
| 2022-12-31 | $35.37 Million | -43.47% |
| 2021-12-31 | $62.58 Million | -21.00% |
| 2020-12-31 | $79.22 Million | +2217.60% |
| 2019-12-31 | $3.42 Million | -79.82% |
| 2018-12-31 | $16.93 Million | +65.01% |
| 2017-12-31 | $10.26 Million | +2264.75% |
| 2016-12-31 | $-474.09K | -105.77% |
| 2015-12-31 | $8.21 Million | +107.18% |
| 2014-12-31 | $3.96 Million | +127.78% |
| 2013-12-31 | $-14.27 Million | -22.71% |
| 2012-12-31 | $-11.63 Million | -3751.77% |
| 2011-12-31 | $318.34K | +165.69% |
| 2010-12-31 | $-484.58K | -138.22% |
| 2009-12-31 | $1.27 Million | -46.27% |
| 2008-12-31 | $2.36 Million | +2362.29% |
| 2007-12-31 | $-104.30K | -104.41% |
| 2006-12-31 | $2.36 Million | +2949.43% |
| 2005-12-31 | $-82.93K | -38.21% |
| 2004-12-31 | $-60.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cytosorbents Crp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 31203700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $63.00K | 1.07% |
| Other Comprehensive Income | $-2.98 Million | -50.43% |
| Other Components | $321.02 Million | 5438.32% |
| Total Equity | $5.90 Million | 100.00% |
Cytosorbents Crp Competitors by Market Cap
The table below lists competitors of Cytosorbents Crp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GoldArc Resources Limited
AU:GA8
|
$22.69 Million |
|
Fusemachines Inc. Common stock
NASDAQ:FUSE
|
$22.69 Million |
|
Grafton Group plc
LSE:GFTU
|
$22.69 Million |
|
Ras Technology Holdings Ltd
AU:RTH
|
$22.70 Million |
|
MESB Bhd
KLSE:7234
|
$22.66 Million |
|
Invoicery Group AB
ST:FRILAN
|
$22.66 Million |
|
Kothari Sugars And Chemicals Limited
NSE:KOTARISUG
|
$22.66 Million |
|
Jupiter Energy Ltd
AU:JPR
|
$22.65 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cytosorbents Crp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 11,106,936 to 5,903,000, a change of -5,203,936 (-46.9%).
- Net loss of 8,198,000 reduced equity.
- New share issuances of 5,392,000 increased equity.
- Other comprehensive income decreased equity by 7,229,013.
- Other factors increased equity by 4,831,077.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.20 Million | -138.88% |
| Share Issuances | $5.39 Million | +91.34% |
| Other Comprehensive Income | $-7.23 Million | -122.46% |
| Other Changes | $4.83 Million | +81.84% |
| Total Change | $- | -46.85% |
Book Value vs Market Value Analysis
This analysis compares Cytosorbents Crp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.81x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $-0.19 | $0.36 | x |
| 2005-12-31 | $-0.27 | $0.36 | x |
| 2006-12-31 | $2.42 | $0.36 | x |
| 2007-12-31 | $-0.10 | $0.36 | x |
| 2008-12-31 | $2.35 | $0.36 | x |
| 2009-12-31 | $0.76 | $0.36 | x |
| 2010-12-31 | $-0.12 | $0.36 | x |
| 2011-12-31 | $0.05 | $0.36 | x |
| 2012-12-31 | $-1.47 | $0.36 | x |
| 2013-12-31 | $-1.51 | $0.36 | x |
| 2014-12-31 | $0.28 | $0.36 | x |
| 2015-12-31 | $0.33 | $0.36 | x |
| 2016-12-31 | $-0.02 | $0.36 | x |
| 2017-12-31 | $0.37 | $0.36 | x |
| 2018-12-31 | $0.55 | $0.36 | x |
| 2019-12-31 | $0.11 | $0.36 | x |
| 2020-12-31 | $2.04 | $0.36 | x |
| 2021-12-31 | $1.44 | $0.36 | x |
| 2022-12-31 | $0.81 | $0.36 | x |
| 2023-12-31 | $0.52 | $0.36 | x |
| 2024-12-31 | $0.20 | $0.36 | x |
| 2025-12-31 | $0.09 | $0.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cytosorbents Crp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -138.88%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -22.12%
- • Asset Turnover: 0.84x
- • Equity Multiplier: 7.48x
- Recent ROE (-138.88%) is above the historical average (-184.79%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 0.00% | -800.00% | 0.33x | 0.00x | $-74.00K |
| 2005 | 0.00% | -800.00% | 0.53x | 0.00x | $-71.71K |
| 2006 | -324.65% | 0.00% | 0.00x | 1.46x | $-7.91 Million |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.34 Million |
| 2008 | -127.90% | 0.00% | 0.00x | 1.44x | $-3.25 Million |
| 2009 | -215.88% | 0.00% | 0.00x | 1.77x | $-2.86 Million |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.86 Million |
| 2011 | -1721.93% | -15193.88% | 0.02x | 6.67x | $-5.51 Million |
| 2012 | 0.00% | -2416.98% | 0.05x | 0.00x | $-2.50 Million |
| 2013 | 0.00% | -569.22% | 0.20x | 0.00x | $-3.25 Million |
| 2014 | -235.20% | -296.38% | 0.37x | 2.14x | $-9.72 Million |
| 2015 | -99.04% | -200.50% | 0.36x | 1.37x | $-8.95 Million |
| 2016 | 0.00% | -145.49% | 0.85x | 0.00x | $-11.89 Million |
| 2017 | -82.44% | -63.23% | 0.56x | 2.35x | $-9.49 Million |
| 2018 | -101.63% | -84.98% | 0.62x | 1.93x | $-18.90 Million |
| 2019 | -563.66% | -84.63% | 0.83x | 8.01x | $-19.61 Million |
| 2020 | -9.89% | -19.86% | 0.44x | 1.14x | $-15.76 Million |
| 2021 | -39.24% | -61.23% | 0.45x | 1.43x | $-30.82 Million |
| 2022 | -92.76% | -94.59% | 0.55x | 1.79x | $-36.35 Million |
| 2023 | -125.66% | -94.09% | 0.58x | 2.29x | $-31.57 Million |
| 2024 | -186.54% | -58.21% | 0.75x | 4.27x | $-21.83 Million |
| 2025 | -138.88% | -22.12% | 0.84x | 7.48x | $-8.79 Million |
Industry Comparison
This section compares Cytosorbents Crp's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $411,255,254
- Average return on equity (ROE) among peers: -85.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cytosorbents Crp (CTSO) | $2.19 Million | 0.00% | 17.49x | $22.67 Million |
| Abbott Laboratories (ABT) | $3.67 Billion | 38.07% | 1.09x | $183.80 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $8.40 Million |
| Aethlon Medical Inc (AEMD) | $1.50 Million | -324.29% | 0.70x | $867.97K |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $903.35K |
| Adapthealth Corp (AHCO) | $280.85 Million | -57.55% | 5.46x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $4.45 Million |
| Allurion Technologies, Inc. (ALUR) | $-34.28 Million | 0.00% | 0.00x | $13.77 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $5.89 Million | -283.55% | 0.29x | $1.87 Million |
| Artivion Inc (AORT) | $121.54 Million | 6.06% | 0.22x | $1.16 Billion |
| Apyx Medical Inc (APYX) | $6.01 Million | -36.31% | 0.22x | $171.68 Million |
About Cytosorbents Crp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and criti… Read more